Clinical Trial Detail

NCT ID NCT02819843
Title A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Advanced Solid Tumor

Merkel cell carcinoma

melanoma

Therapies

Talimogene laherparepvec

Age Groups: adult senior

No variant requirements are available.